Gilead Sciencesvs.United Therapeutics
GILD vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 8.1× larger than United Therapeutics by market cap; year to date, Gilead Sciences leads (+19.8% vs +9.3%).
Side by side
| GILD | UTHR | |
|---|---|---|
| Market cap | $186B | $22.9B |
| Price | $151.17 | $549.16 |
| Today | +2.8% | +3.1% |
| Return YTD | +19.8% | +9.3% |
| Return 1Y | +24.4% | +18.7% |
| Since June 26, 2026 | +18.2% | +1.2% |
| P/E | — | 17.4 |
| P/S | 6.1 | 7.2 |
| P/B | 15.7 | 3.6 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More GILD & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.